Gyre Therapeutics (GYRE) Assets Average (2011 - 2026)

Gyre Therapeutics (GYRE) has 16 years of Assets Average data on file, last reported at $164.1 million in Q1 2026.

• Quarterly Assets Average rose 28.59% year-over-year to $164.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $164.1 million (up 28.59% YoY) and the FY2025 annual result came in at $145.8 million, up 20.5% from the prior year.
• Assets Average rose to $164.1 million in Q1 2026 per GYRE's latest filing, from $162.8 million in the prior quarter.
• Across five years, Assets Average topped out at $164.1 million in Q1 2026 and bottomed at $11.2 million in Q3 2023.
• The 5-year median for Assets Average is $119.3 million (2024), against an average of $94.6 million.
• The widest annual swing landed in 2023, when Assets Average slumped 80.45%; it then jumped 1001.03% in 2024.
• Tracing GYRE's Assets Average over 5 years: stood at $57.9 million in 2022, then increased by 9.27% to $63.3 million in 2023, then jumped by 98.13% to $125.3 million in 2024, then grew by 29.87% to $162.8 million in 2025, then increased by 0.81% to $164.1 million in 2026.
• Per Business Quant, the three latest GYRE Assets Average figures stand at $164.1 million (Q1 2026), $162.8 million (Q4 2025), and $156.0 million (Q3 2025).

Peer Comparison